Israeli venture capital firm Viola Ventures has closed its sixth fund of $250 million to invest in early-stage Israeli startups focused on areas like fintech, deep tech, digital health, enterprise infrastructure, software, Web 3.0, and cybersecurity, the company announced on Thursday.
Viola said it now has over $1.25 billion in assets under management and will invest in 25-30 new startups with the new fund. The VC firm has backed leading Israeli companies such as fintech firm Payoneer, content creation app company Lightricks, transcription company Verbit, and biotech startup Immunai.
In 2021, Viola said eight of its portfolio companies reached unicorn status, becoming valued at $1 billion or more, amid a bumper year for the Israeli tech industry. Last year, Israeli companies raised over $25 billion in funding with at least 33 companies becoming unicorns.
“Our track record proves that we know how to identify outstanding teams, aggressively be the first money, and then support them to unicorn status and beyond. We are confident that our sixth fund will help grow the next generation of market leaders,” said Danny Cohen, general partner at Viola Ventures, in a statement.
Viola Ventures “invested less than 0.5% of the capital deployed in Israel in 2021 and has ~15% of Israel’s total unicorns, ” added Omry Ben David, also a general partner at Viola Ventures. “The Israeli tech ecosystem is definitely evolving. Israeli entrepreneurs have growing aspirations and we are seeing more Israeli companies going public and staying independent, thus controlling their own destiny for longer.”
Sign up for the Tech Israel Daily and never miss Israel’s top tech stories
By signing up, you agree to the terms
Based in Tel Aviv, Viola Ventures has invested in close to 90 companies so far including SimilarWeb, Outbrain, Guesty, and Bringg.
Telling an urgent story
During a global pandemic, one tiny country is producing research that’s helping to guide health policy across the world. How effective are COVID-19 vaccines? After the initial two shots, does a third dose help? What about a fourth?
When The Times of Israel began covering COVID-19, we had no idea that our small beat would become such a central part of the global story. Who could have known that Israel would be first at nearly every juncture of the vaccination story – and generate the research that’s so urgently needed today?
Our team has covered this story with the rigor and accuracy that characterizes Times of Israel reporting across topics. If it’s important to you that this kind of media organization exists and thrives, I urge you to support our work. Will you join The Times of Israel Community today?
Thank you,
Nathan Jeffay, Health & Science Correspondent
Join our Community
Join our Community
Already a member? Sign in to stop seeing this
You’re serious. We appreciate that!
We’re really pleased that you’ve read X Times of Israel articles in the past month.
That’s why we come to work every day – to provide discerning readers like you with must-read coverage of Israel and the Jewish world.
So now we have a request. Unlike other news outlets, we haven’t put up a paywall. But as the journalism we do is costly, we invite readers for whom The Times of Israel has become important to help support our work by joining The Times of Israel Community.
For as little as $6 a month you can help support our quality journalism while enjoying The Times of Israel AD-FREE, as well as accessing exclusive content available only to Times of Israel Community members.
New York Tech Media is a leading news publication that aims to provide the latest tech news, fintech, AI & robotics, cybersecurity, startups & leaders, venture capital, and much more!
